)
)
)
7 Hills Pharma is a clinical-stage company advancing first-in-class small molecules leveraging a novel mechanism of action, pioneered by 7HP founders, to safely enhance the effectiveness of immunotherapies against treatment-resistant solid tumors, with no added toxicities. Our platform of selective integrin activators optimize multiple rate-limiting immune cell adhesion events to overcome resistance and drive a productive anti-tumor immune response. Our unique mechanism of action attacks a fundamental pathway of tumor immune evasion. In a Phase Ib/IIa clinical trial testing alintegimod, our first clinical-stage molecule, in combination with sequential dual checkpoint blockade against aPD-1-resistant solid tumors, we have so far treated 12 patients, with encouraging early biomarker observations, disease control, and a partial response. The Phase Ib data readout is expected mid-2026.
Year Founded
2014
Next catalyst (value inflection) update
Phase Ib data readout from alintegimod clinical trial
Expected time of next catalyst update
Jul-26
City
Houston
Country
United States
Company CEO or top company official
Upendra Marathi
Development Phase of Primary Product
Phase I
Lead Product in Development
alintegimod
Therapeutic Area
Oncology
Website
https://www.7hillspharma.com/
){kind=logo}
)
)
){kind=logo}
)
){kind=logo}
){kind=logo}
){kind=logo}
